CoChat

Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.

Open access
Zinman, Bernard, Aroda, Vanita R., Buse, John B., Cariou, Bertrand, Harris, Stewart B., Hoff, Søren Tetens, Pedersen, Karen Boje, Tarp-Johansen, Mads Jeppe, Araki, Eiichi, PIONEER 8 Investigators, Zinman, Bernard, Fikry, Sameh, Bajaj, Harpreet, Landry, Daniel, Caplan, David, Woo, Vincent, Harris, Stewart, Thuan, Jean-Francois, Serusclat, Pierre, Cariou, Bertrand, Gourdy, Pierre, Fradet, Gerard, Monier, Arnaud, Borot, Sophie, Monguillon, Pascal, Gouet, Didier, Doupis, John, Tentolouris, Nikolaos, Tsimichodimos, Vasileios, Melidonis, Andreas, Bekiari, Eleni, Bargiota, Alexandra, Agarwal, Sanjay, Saboo, Banshi, Chatterjee, Sanjay, Mohan, Viswanathan, Shaikh, Shehla, Gupta, Yashdeep, Bhattacharyya, Arpandev, Manikath, Neeraj, Jain, Sunil, Sasaki, Takashi, Osonoi, Takeshi, Fukuda, Shuichi, Wada, Seiki, Kiyosue, Arihiro, Ide, Yumiko, Onishi, Yukiko, Matoba, Kiyokazu, Takai, Kuninobu, Yamauchi, Akira, Inoue, Satoshi, Kaneko, Shizuka, Ikeda, Hiroki, Ohta, Yasuharu, Hisatomi, Akitaka, Senokuchi, Takafumi, Jinnouchi, Hideaki, Nakamura, Shuji, Soto, José Roberto Lazcano, Briones, Ignacio Rodriguez, Bogdanski, Pawel, Szyprowska, Ewa, Modzelewska, Anna, Wozniak, Iwona, Zyangirova, Svetlana, Sergeeva-Kondrachenko, Marina, Davis, Thomas, Thomson, Stephen, Frias, Juan, Gandy, Winston, Lingvay, Ildiko, Pounds, Kevin, Bowman-Stroud, Cynthia, Dempsey, Michael, Huffman, David, Ahmed, Azazuddin, Fraser, Neil, Ortiz-Carrasquillo, Ramon, Bolster, D. Eric, Adams, Michael, Hummel, Matthew, Free, Almena, Houser, Patricia, Shockey, Gerald, Barnum, Otis, Bhasker, Kala, Cornett, George, Streja, Dan, Kirby, William, Lynd, Sean, Folkerth, Steven, Nakhle, Samer, Norwood, Paul, Perez, Rodolfo, Snyder, Brian, Farris, Neil, Litchfield, Willian, Hamdy, Osama, Park, Jean, Aroda, Vanita, Buse, Joh · 2019 · Diabetes Care

The DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double-blind trial. End points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands were defined: treatment policy (effect regardless of trial product discontinuation or rescue medication) and trial product (effect assuming trial product continuation without rescue medication) in randomized patients. RESULTS: Oral semaglutide was superior to placebo in reducing HbA1c (estimated treatment difference [ETD] –0.5% [95% CI –0.7, –0.3], –0.9% [–1.1, –0.7], and –1.2% [–1.4, –1.0] for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD −0.9 kg [95% CI −1.8, −0.0], −2.0 kg [−3.0, −1.0], and −3.3 kg [−4.2, −2.3]; P = 0.0392 for 3 mg, P ≤ 0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater dose-dependent HbA1c and body weight reductions versus placebo were achieved with oral semaglutide at weeks 26 and 52 (both estimands). The most frequent adverse event with oral semaglutide was nausea (11.4–23.2% of patients vs. 7.1% with placebo; mostly mild to moderate). CONCLUSIONS: Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc19-0898

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

Items 301–319 of 319

Metadata

Authors
Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, Zinman, B., Fikry, S., Bajaj, H., Landry, D., Caplan, D., Woo, V., Harris, S., Thuan, J.-F., Serusclat, P., Cariou, B., Gourdy, P., Fradet, G., Monier, A., Borot, S., Monguillon, P., Gouet, D., Doupis, J., Tentolouris, N., Tsimichodimos, V., Melidonis, A., Bekiari, E., Bargiota, A., Agarwal, S., Saboo, B., Chatterjee, S., Mohan, V., Shaikh, S., Gupta, Y., Bhattacharyya, A., Manikath, N., Jain, S., Sasaki, T., Osonoi, T., Fukuda, S., Wada, S., Kiyosue, A., Ide, Y., Onishi, Y., Matoba, K., Takai, K., Yamauchi, A., Inoue, S., Kaneko, S., Ikeda, H., Ohta, Y., Hisatomi, A., Senokuchi, T., Jinnouchi, H., Nakamura, S., Soto, J. R. L., Briones, I. R., Bogdanski, P., Szyprowska, E., Modzelewska, A., Wozniak, I., Zyangirova, S., Sergeeva-Kondrachenko, M., Davis, T., Thomson, S., Frias, J., Gandy, W., Lingvay, I., Pounds, K., Bowman-Stroud, C., Dempsey, M., Huffman, D., Ahmed, A., Fraser, N., Ortiz-Carrasquillo, R., Bolster, D. E., Adams, M., Hummel, M., Free, A., Houser, P., Shockey, G., Barnum, O., Bhasker, K., Cornett, G., Streja, D., Kirby, W., Lynd, S., Folkerth, S., Nakhle, S., Norwood, P., Perez, R., Snyder, B., Farris, N., Litchfield, W., Hamdy, O., Park, J., Aroda, V., & Buse, J.
Affiliations
  • Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
  • University of North Carolina at Chapel Hill (US)
  • Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
  • Novo Nordisk A/S, Søborg, Denmark
  • Novo Nordisk (Denmark) (DK)
  • Kumamoto University (JP)
Venue
Diabetes Care
Published
2019-07-10
Volume
42
Issue
12
Pages
2262-2271
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2974714926
Cited by
300
References
37
Citations by year
2026: 28 · 2025: 62 · 2024: 51 · 2023: 32 · 2022: 39 · 2021: 43 · 2020: 41 · 2019: 3
FWCI
25.55
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • American Diabetes Association
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • CSL Behring
  • Regeneron Pharmaceuticals
  • Les Laboratories Pierre Fabre
  • MannKind Corporation
  • Kowa Company
  • Zafgen
  • Boehringer Ingelheim Japan
  • Eisai
  • Novo Nordisk (U54-DK-118612, UC4-DK-108612, UL1-TR-002489)
  • Astellas Pharma
  • Shionogi
  • Terumo
  • Mitsubishi Tanabe Pharma Corporation
  • Ono Pharmaceutical
  • National Institutes of Health (UL1TR002489, UL1-TR-)
  • Japan Society for the Promotion of Science (17H04201, 18K08482)
  • National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK108612, U01DK098246, U54DK118612)
  • National Center for Advancing Translational Sciences
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
oral semaglutide, type 2 diabetes, insulin, metformin, glycemic control, HbA1c, weight loss, nausea, GLP-1 receptor agonists, treatment policy estimand, dose-dependent effects, uncontrolled diabetes, adverse events, tolerability, rescue medication, treatment discontinuation
MeSH terms
Semaglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Nausea, Weight Loss, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.